CSL Behring Professor Heimburger Award
Global Research Grant – Coagulation
CSL Behring is committed to supporting long-range progress in the area of coagulation. Based on recent publications and feedback from the medical community, it is important to encourage the next generation of coagulation specialists to medically and scientifically establish themselves, in order to have continued progress in this therapeutic area. CSL Behring will fund the second cycle of a global grant program to support the above objective.
Professor Dr. Norbert Heimburger
Prof. Dr. Norbert Heimburger, a CSL Behring employee for over three decades, devoted his work to blood coagulation. During that time, he characterized and purified a large number of plasma proteins and was instrumental in making these available to the medical community as therapeutic options. One of his major contributions in this area was the development of virus-safe plasma products based on pasteurization.
Due to his determination and constant interaction with leading hemophilia and coagulation specialists, Behring launched the first effectively virus-inactivated FVIII concentrate in 1981. Prof. Dr. Heimburger, honored with the Order of Merit of the Federal Republic of Germany in 1991, retired in 1991 but was still very much involved with CSL Behring as a Scientific Advisor until he passed away in September 2006.
CSL Behring named this grant “CSL Behring - Professor Heimburger Award” to honor Professor Dr. Heimburger.
Funds Available
CSL Behring will offer five (5) global start-up grants of € 20.000 each for the 2009 cycle. No matching funding is a prerequisite for this grant. The grants will be available for preclinical and/or clinical research in the area of coagulation. All applications will be forwarded to a selection committee consisting of four scientifically renowned clinicians in the field of coagulation.
At the end of the year, the recipient will have the opportunity to present the results at CSL Behring, Marburg, Germany.
Eligibility
The grants are targeted at investigators relatively new to the field of coagulation, who hold an MD and who wish to establish their own independent research project in the field of coagulation. It is expected that the person indicated as the investigator for this grant application is the individual who is personally and actively responsible to conduct the research.
Application Procedures
Apply in one of these ways:
- Complete the
online application form, save it, and e-mail it to heimburger.award@cslbehring.com
- Download an
application form and send it via the postal service to the address below.
- Request one or more hard copies of the application form by mail from the address below, and return the completed form(s) by the postal service to that address.
CSL Behring
Commercial Development Coagulation
Emil-von-Behring-Strasse 76
35041 Marburg
GERMANY
Applications consisting of application form, current CV and one-page research proposal must be received by CSL Behring no later than 17 October, 2008 to be considered for the next cycle. Applications should be submitted to the address above. Please note that applications can also be submitted online.
All applications will be forwarded to a selection committee consisting of four scientifically renowned clinicians in the field of coagulation:
Erik Berntorp, MD, PhD
Centre for Thrombosis and Haemostasis
Malmö University Hospital, Malmö, Sweden
Jorge Di Paola, MD
Department of Pediatrics
University of Iowa Hospitals and Clinics, Iowa City, USA
David Lillicrap, MD
Department of Pathology and Molecular Medicine
Queen's University, Kingston, Canada
Johannes Oldenburg, MD
Institute of Experimental Haematology
and Transfusion Medicine
University Clinic Bonn, Bonn, Germany
The selection committee will review applications based solely on scientific merit. Applications will initially be screened and the 10 applicants deemed to have the highest chance of success will be asked to submit a more detailed (3-4 page) description of their research project.
Based on their evaluation of the detailed submission, the selection committee will inform CSL Behring of their decision by 15 February, 2009. CSL Behring will then notify the recipients. Grants will be personally awarded by CSL Behring in March 2009.
More Information
Research Grant Statutes can be downloaded as a printable PDF.
Note: To view this document, you must have Adobe Acrobat Reader 8.1.1 installed. Reader 8.1.1. is available as a free download from Adobe Systems. Inc.
Inquiries
For questions regarding applications, policy and procedures information, contact:
CSL Behring GmbH
Att. Dieter Pluennecke
Commercial Development Coagulation
Emil-von-Behring-Strasse 76
35041 Marburg
GERMANY
T: +49 6421 394191
F: +49 6421 394146
e-mail: heimburger.award@cslbehring.com
About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe, effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.
Coagulation Portfolio of CSL Behring
